Chronicle Bio
PrivateLast Round
Seed
Jan 1, 2026
Total Funding Raised
$5.36M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Chronicle Bio operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Seed round in January 2026.
Chronicle Bio is a biotechnology company that has developed a data-driven healthcare platform designed to accelerate drug discovery for neuroimmune conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Subscription SaaS, Services & Consulting
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Chronicle Bio Comparables
Compare Chronicle Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PrecisionLife | 74% | |
| Betteromics | 70% | |
| IMU Biosciences | 69% |
For institutional investors. Book with your work email.
Chronicle Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 1, 2026 | ||||
| Seed Round | Sep 30, 2025 |
For institutional investors. Book with your work email.
Chronicle Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wisdom Ventures | Seed Round, Seed |
| Electric Capital | Seed Round, Seed |
| Tarsadia Investments | Seed Round, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
Open roles increased to 5, representing 23% of headcount.
- Jan 1, 2026
$5.36M round led by Tarsadia Investments and Electric Capital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 12, 2026
ChronicleBio and Prolong Pharmaceuticals, LLC announce a partnership on Nov 12th '26 to evaluate PP-007 as a potential ME/CFS treatment through a planned multi-site Phase 2a trial involving at least 40 patients, with first treatments expected in mid-2027.
For institutional investors. Book with your work email.
Chronicle Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Chronicle Bio's valuation, stock price, and market status.
Is Chronicle Bio a public or private company?
Chronicle Bio is a private company.
What is the current stock price of Chronicle Bio?
Chronicle Bio is a private company, so its shares have no public market price. Caplight tracks Chronicle Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Chronicle Bio worth (valuation)?
Valuation information for Chronicle Bio is not publicly available.
Can I buy Chronicle Bio stock?
Chronicle Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Chronicle Bio's last funding round?
Chronicle Bio's most recent funding round was Seed on January 1, 2026.
Who are the main investors in Chronicle Bio?
Key investors in Chronicle Bio include Wisdom Ventures, Electric Capital, Tarsadia Investments.
Will Chronicle Bio IPO soon?
No public IPO plans have been announced for Chronicle Bio.
How can I track Chronicle Bio secondary market activity?
Caplight tracks bids, offers, and trades in Chronicle Bio's shares on secondary markets.